ClinicalTrials.gg
CompletedNCT03252015Updated Jan 10, 2020Results posted

A Study of Multiple Doses of Lasmiditan in Healthy Participants

A Phase 1 interventional study of Probe Drug Cocktail and Lasmiditan in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-10.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to look at how much lasmiditan, study drug, gets into the blood stream and how long it takes the body to get rid of it.

When drugs are taken together, one or all of the drugs used in combination may be affected. This study will also evaluate the concentrations in the blood of a probe drug cocktail taken alone and in combination with lasmiditan. Information about any side effects that may occur will also be collected.

The study has two parts. Participants will only enroll in one part. This study will last about 25 days for group 1 and 22 days for group 2, not including screening. Screening is required within 28 days prior to the start of the study.

This study is for research purposes only and is not intended to treat any medical condition.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.

Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males or females, as determined by medical history and physical examination
  • Have a (BMI) of 19.0 to 35.0 kilograms per meter squared (kg/m²) inclusive, at the time of screening

Exclusion criteria

Exclusion Criteria:

  • Have participated, within the last 30 days, in a clinical study involving an Product (IP)
  • Have previously completed or withdrawn from this study or any other study investigating Lasmiditan, and have previously received Lasmiditan
  • Have abnormality in the 12-lead , including interval (QTc) with Fridericia's correction (QTcF) greater than (>) 450 milliseconds (ms) for men or >470 ms for women or any abnormality that in the opinion of the investigator increases the risk of participating in the study (not limited to significant bradycardia or heart block)
  • History of, show evidence of, or are undergoing treatment for significant active neuropsychiatric disease (for example, manic depressive illness, schizophrenia, depression), have a recent history of a suicide attempt (30 days within screening visit and any time between screening visit and baseline); or are clinically judged by the investigator to be at risk for suicide
  • History of hypoglycemia
  • Known history of glucose-6-phosphate dehydrogenase deficiency
  • Are taking a concomitant medication or a dietary substance that affects cytochrome P450 (CYP)1A2, CYP2C9, and/or isotypes within 14 days of screening
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Probe Drug Cocktail (Cohort 1a)

    Probe Drug Cocktail administered orally on Day -3.

    Drug: Probe Drug Cocktail

  • Experimental
    200 milligrams (mg) Lasmiditan+Probe Drug Cocktail (Cohort 1)

    200 mg lasmiditan administered alone, orally, on Days 1-6 and concurrently with probe drug cocktail on Day 7.

    Drug: Probe Drug Cocktail · Drug: Lasmiditan

  • Placebo comparator
    Placebo+Probe Drug Cocktail (Cohort 1b)

    Placebo administered alone, orally, on Days 1-6 and concurrently with probe drug cocktail on Day 7.

    Drug: Probe Drug Cocktail · Drug: Placebo

  • Experimental
    400 mg Lasmiditan (Cohort 2a)

    400 mg lasmiditan administered orally for 7 days.

    Drug: Lasmiditan

  • Experimental
    Placebo (Cohort 2b)

    Placebo administered orally for 7 days.

    Drug: Placebo

Interventions

  • DrugProbe Drug Cocktail

    Administered orally

  • Administered orally

    Also known as: LY573144

  • DrugPlacebo

    Administered orally

06

What researchers measure

Primary outcomes

  1. Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module. Adverse events for this outcome measure are reported by arm. SAEs are reported by study drug in the Adverse Events module.

    Time frame: Baseline through 14 days after last administration of study drug

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Lasmiditan on Day 1

    PK: Cmax of lasmiditan

    Time frame: Lasmiditan PK: Day 1:0.5 hour (hr), 1hr , 1.5hr, 2hr, 2.5hr, 3hr, 4hr, 6hr, 8hr, 12hr, 24hr and 48 hr postdose

  2. Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Lasmiditan on Day 7

    PK: Cmax of lasmiditan Day 7

    Time frame: Lasmiditan PK: Day 7: 0.5hour(hr), 1hr, 1.5hr, 2hr, 2.5hr, 3hr, 4hr, 6hr, 8hr, 12hr, 24hr postdose

  3. Pharmacokinetics (PK): Area Under the Concentration Curve to the End of the Dosing Period (AUC[Tau]) Lasmiditan on Day 1

    PK: AUCtau of lasmiditan

    Time frame: Day 1:0.5 hour (hr), 1hr , 1.5hr, 2hr, 2.5hr, 3hr, 4hr, 6hr, 8hr, 12hr, and 24hr postdose

  4. Pharmacokinetics (PK): Area Under the Concentration Curve to the End of the Dosing Period (AUC[Tau]) Lasmiditan on Day 7

    PK AUCtau of lasmiditan

    Time frame: Lasmiditan PK: Day 7: 0.5hour(hr), 1hr, 1.5hr, 2hr, 2.5hr, 3hr, 4hr, 6hr, 8hr, 12hr,and 24hr postdose

  5. Benzodiazepine Withdrawal Symptom Questionnaire (BWSQ) Total Score

    BWSQ is a 20 item, self administered withdrawal symptom questionnaire. Each question is scored by a 0 representing no withdrawal symptoms, 1 for moderate symptoms, 2 for severe symptoms. Total score at each time point will be averaged for each treatment in each cohort.

    Time frame: PreDose Day 7 and Day 21

  6. Physician Withdrawal Checklist (PWC)Total Score

    Physician Withdrawal Checklist (PWC) : 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.

    Time frame: Day 7 and Day 21 at anytime

  7. Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Metabolite M8 on Day 1

    Cmax of M8 on Day 1 following a single and repeated oral daily dosing of 200 and 400 mg lasmiditan. M8 is a metabolite of lasmiditan.

    Time frame: Day 1: 0.5 hr, 1hr, 1.5hr, 2 hr, 2.5hr, 3hr, 4hr, 6hr, 8hr, 12hr, 24 hr adn 48 hr postdose

  8. Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Metabolite M8 on Day 7

    Cmax of M8 on Day 7 following a single and repeated oral daily dosing of 200 and 400 mg lasmiditan. M8 is a metabolite of lasmiditan.

    Time frame: Day 7: Predose, 0.5hr, 1hr, 1.5hr, 2hr, 2.5hr, 3hr, 4hr, 6hr, 8hr, 12hr, 24 hr and 48 hr postdose

  9. Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Midazolam

    PK: Cmax of midazolam.

    Time frame: Day -3: Predose, 0.5 hour(hr), 1hr, 1.5hr. 2hr, 2.5hr, 3hr, 4hr, 6hr, 8hr, and 12 hr postdose,

  10. Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Midazolam on Day 7

    PK of midazolam.

    Time frame: Day 7:Predose, 0,5hr,1hr, 1.5hr. 2hr, 2.5hr, 3hr, 4hr, 6hr, 8hr, and 12 hr postdose

07

Results

Posted Jan 10, 2020

Participant flow

Participant flow — Overall Study
MilestoneCohort 1a (Placebo+Probe Drug Cocktail)Cohort 1b (200 mg Lasmiditan+Probe Drug Cocktail)Cohort 2a (Placebo)Cohort 2b (400 mg Lasmiditan)
Started12281515
Received at least 1 dose of study drug12281515
Completed11271414
Not completed1111
Withdrew: Withdrawal by subject0110
Withdrew: Adverse event1001

Outcome measures

PrimaryNumber of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module. Adverse events for this outcome measure are reported by arm. SAEs are reported by study drug in the Adverse Events module.

Time frame:
Baseline through 14 days after last administration of study drug
Reported as:
Count of participants · Participants
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
ParticipantsCohort 1a (Placebo+Probe Drug Cocktail)Cohort 1b (200 mg Lasmiditan+Probe Drug Cocktail)Cohort 2a (Placebo)Cohort 2b (400 mg Lasmiditan)
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration0000
SecondaryPharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Lasmiditan on Day 1

PK: Cmax of lasmiditan

Time frame:
Lasmiditan PK: Day 1:0.5 hour (hr), 1hr , 1.5hr, 2hr, 2.5hr, 3hr, 4hr, 6hr, 8hr, 12hr, 24hr and 48 hr postdose
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Lasmiditan on Day 1
nanograms per milliliter (ng/mL)200 mg Lasmiditan400 mg Lasmiditan
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Lasmiditan on Day 1349 ± 32750 ± 44
SecondaryPharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Lasmiditan on Day 7

PK: Cmax of lasmiditan Day 7

Time frame:
Lasmiditan PK: Day 7: 0.5hour(hr), 1hr, 1.5hr, 2hr, 2.5hr, 3hr, 4hr, 6hr, 8hr, 12hr, 24hr postdose
Reported as:
Geometric mean · ng/mL
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Lasmiditan on Day 7
ng/mL200 mg Lasmiditan400 mg Lasmiditan
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Lasmiditan on Day 7353 ± 29808 ± 41
SecondaryPharmacokinetics (PK): Area Under the Concentration Curve to the End of the Dosing Period (AUC[Tau]) Lasmiditan on Day 1

PK: AUCtau of lasmiditan

Time frame:
Day 1:0.5 hour (hr), 1hr , 1.5hr, 2hr, 2.5hr, 3hr, 4hr, 6hr, 8hr, 12hr, and 24hr postdose
Reported as:
Geometric mean · nanograms times hour per milliLiter
Pharmacokinetics (PK): Area Under the Concentration Curve to the End of the Dosing Period (AUC[Tau]) Lasmiditan on Day 1
nanograms times hour per milliLiterCohort 1b (200 mg Lasmiditan+Probe Drug Cocktail)Cohort 2b (400 mg Lasmiditan)
Pharmacokinetics (PK): Area Under the Concentration Curve to the End of the Dosing Period (AUC[Tau]) Lasmiditan on Day 12070 ± 324530 ± 39
SecondaryPharmacokinetics (PK): Area Under the Concentration Curve to the End of the Dosing Period (AUC[Tau]) Lasmiditan on Day 7

PK AUCtau of lasmiditan

Time frame:
Lasmiditan PK: Day 7: 0.5hour(hr), 1hr, 1.5hr, 2hr, 2.5hr, 3hr, 4hr, 6hr, 8hr, 12hr,and 24hr postdose
Reported as:
Geometric mean · nanograms time hours per milliLiter
Pharmacokinetics (PK): Area Under the Concentration Curve to the End of the Dosing Period (AUC[Tau]) Lasmiditan on Day 7
nanograms time hours per milliLiter200 mg Lasmiditan+Probe Drug Cocktail (Cohort 1)400 mg Lasmiditan (Cohort 2)
Pharmacokinetics (PK): Area Under the Concentration Curve to the End of the Dosing Period (AUC[Tau]) Lasmiditan on Day 72160 ± 294690 ± 36
SecondaryBenzodiazepine Withdrawal Symptom Questionnaire (BWSQ) Total Score

BWSQ is a 20 item, self administered withdrawal symptom questionnaire. Each question is scored by a 0 representing no withdrawal symptoms, 1 for moderate symptoms, 2 for severe symptoms. Total score at each time point will be averaged for each treatment in each cohort.

Time frame:
PreDose Day 7 and Day 21
Reported as:
Mean · units on a scale
Benzodiazepine Withdrawal Symptom Questionnaire (BWSQ) Total Score
units on a scaleCohort 1a (Placebo+Probe Drug Cocktail)Cohort 1b (200 mg Lasmiditan+Probe Drug Cocktail)Cohort 2a (Placebo)Cohort 2b (400 mg Lasmiditan)
Day 70.0 ± 0.00.2 ± 0.60.0 ± 0.00.1 ± 0.3
Day 210.0 ± 0.00.0 ± 0.00.0 ± 0.00.0 ± 0.0
Statistical analysis
  • Cohort 1a (Placebo+Probe Drug Cocktail) vs Cohort 1b (200 mg Lasmiditan+Probe Drug Cocktail) · Mean difference (final values): -0.182 · 95% CI -0.412 to 0.049
  • Cohort 2a (Placebo) vs Cohort 2b (400 mg Lasmiditan) · Mean difference (final values): 0.071 · 95% CI -0.081 to 0.224
  • Cohort 1a (Placebo+Probe Drug Cocktail) vs Cohort 1b (200 mg Lasmiditan+Probe Drug Cocktail) · Mean difference (final values): 0.000 · 95% CI 0.000 to 0.000
  • Cohort 2a (Placebo) vs Cohort 2b (400 mg Lasmiditan) · Mean difference (final values): 0.000 · 95% CI 0.000 to 0.000
SecondaryPhysician Withdrawal Checklist (PWC)Total Score

Physician Withdrawal Checklist (PWC) : 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.

Time frame:
Day 7 and Day 21 at anytime
Reported as:
Mean · units on a scale
Physician Withdrawal Checklist (PWC)Total Score
units on a scaleCohort 1a (Placebo+Probe Drug Cocktail)Cohort 1b (200 mg Lasmiditan+Probe Drug Cocktail)Cohort 2a (Placebo)Cohort 2b (400 mg Lasmiditan)
Day 7 Predose0.2 ± 0.40.0 ± 0.20.0 ± 0.00.1 ± 0.3
Day 210.0 ± 0.00.1 ± 0.40.0 ± 0.00.0 ± 0.0
Statistical analysis
  • Cohort 1a (Placebo+Probe Drug Cocktail) vs Cohort 1b (200 mg Lasmiditan+Probe Drug Cocktail) · Mean difference (final values): -0.145 · 95% CI -0.340 to 0.050
  • Cohort 2a (Placebo) vs Cohort 2b (400 mg Lasmiditan) · Mean difference (final values): 0.071 · 95% CI -0.081 to 0.224
  • Cohort 1a (Placebo+Probe Drug Cocktail) vs Cohort 1b (200 mg Lasmiditan+Probe Drug Cocktail) · Mean difference (final values): 0.071 · 95% CI -0.151 to 0.294
  • Cohort 2a (Placebo) vs Cohort 2b (400 mg Lasmiditan) · Mean difference (final values): 0.000 · 95% CI 0.000 to 0.000
SecondaryPharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Metabolite M8 on Day 1

Cmax of M8 on Day 1 following a single and repeated oral daily dosing of 200 and 400 mg lasmiditan. M8 is a metabolite of lasmiditan.

Time frame:
Day 1: 0.5 hr, 1hr, 1.5hr, 2 hr, 2.5hr, 3hr, 4hr, 6hr, 8hr, 12hr, 24 hr adn 48 hr postdose
Reported as:
Geometric mean · mg/mL
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Metabolite M8 on Day 1
mg/mL200 mg Lasmiditan400 mg Lasmiditan
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Metabolite M8 on Day 1407 ± 24964 ± 18
SecondaryPharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Metabolite M8 on Day 7

Cmax of M8 on Day 7 following a single and repeated oral daily dosing of 200 and 400 mg lasmiditan. M8 is a metabolite of lasmiditan.

Time frame:
Day 7: Predose, 0.5hr, 1hr, 1.5hr, 2hr, 2.5hr, 3hr, 4hr, 6hr, 8hr, 12hr, 24 hr and 48 hr postdose
Reported as:
Geometric mean · ng/mL
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Metabolite M8 on Day 7
ng/mL200 mg Lasmiditan+Probe Drug Cocktail (Cohort 1)400 mg Lasmiditan (Cohort 2)
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Metabolite M8 on Day 7641 ± 201500 ± 20
SecondaryPharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Midazolam

PK: Cmax of midazolam.

Time frame:
Day -3: Predose, 0.5 hour(hr), 1hr, 1.5hr. 2hr, 2.5hr, 3hr, 4hr, 6hr, 8hr, and 12 hr postdose,
Reported as:
Geometric mean · nanograms per milliLiter
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Midazolam
nanograms per milliLiterParticipants Who Received Probe Drug Cocktail
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Midazolam10. ± 39
SecondaryPharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Midazolam on Day 7

PK of midazolam.

Time frame:
Day 7:Predose, 0,5hr,1hr, 1.5hr. 2hr, 2.5hr, 3hr, 4hr, 6hr, 8hr, and 12 hr postdose
Reported as:
Geometric mean · nanograms per milliliter
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Midazolam on Day 7
nanograms per milliliterCohort 1a (Placebo+Probe Drug Cocktail)Cohort 1b (200 mg Lasmiditan+Probe Drug Cocktail)
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Midazolam on Day 710.1 ± 409.45 ± 34

Adverse events

Collected over Baseline through 28 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Probe Drug Cocktail (Cohort 1)0/40 (0%)0/40 (0%)0/40 (0%)
200 mg Lasmiditan QD (Cohort 1)0/28 (0%)0/28 (0%)13/28 (46.4%)
200 mg Lasmiditan QD + Probe Drug Cocktail (Cohort 1)0/27 (0%)0/27 (0%)4/27 (14.8%)
Placebo QD (Cohort 1)0/12 (0%)0/12 (0%)5/12 (41.7%)
Placebo QD + Probe Drug Cocktail (Cohort 1)0/11 (0%)0/11 (0%)1/11 (9.1%)
400 mg Lasmiditan QD (Cohort 2)0/15 (0%)0/15 (0%)5/15 (33.3%)
Placebo QD (Cohort 2)0/15 (0%)0/15 (0%)4/15 (26.7%)
Most frequent other events
Showing 10 of 26
Most frequent other events
EventProbe Drug Cocktail (Cohort 1)200 mg Lasmiditan QD (Cohort 1)200 mg Lasmiditan QD + Probe Drug Cocktail (Cohort 1)Placebo QD (Cohort 1)Placebo QD + Probe Drug Cocktail (Cohort 1)400 mg Lasmiditan QD (Cohort 2)Placebo QD (Cohort 2)
DizzinessNervous system disorders0/406/282/270/120/113/150/15
FatigueGeneral disorders0/404/280/270/120/110/150/15
Euphoric moodPsychiatric disorders0/401/280/270/120/112/150/15
ParaesthesiaNervous system disorders0/400/280/270/121/110/150/15
Eye painEye disorders0/401/280/271/120/110/150/15
FolliculitisInfections and infestations0/400/280/271/120/110/150/15
Wrong technique in product usage processInjury, poisoning and procedural complications0/400/280/271/120/110/150/15
Decreased appetiteMetabolism and nutrition disorders0/400/280/271/120/110/150/15
HeadacheNervous system disorders0/400/280/271/120/111/151/15
NervousnessPsychiatric disorders0/400/280/271/120/110/150/15

Baseline characteristics

All participants who received at least 1 dose of study drug

Age, Continuous
Age, Continuous(years)Cohort 1a (Placebo+Probe Drug Cocktail)Cohort 1b (200 mg Lasmiditan+Probe Drug Cocktail)Cohort 2a (Placebo)Cohort 2b (400 mg Lasmiditan)Total
Mean42.8 ± 11.942.9 ± 12.339.5 ± 11.436.9 ± 9.740.9 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1a (Placebo+Probe Drug Cocktail)Cohort 1b (200 mg Lasmiditan+Probe Drug Cocktail)Cohort 2a (Placebo)Cohort 2b (400 mg Lasmiditan)Total
Female6126630
Male6169940
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1a (Placebo+Probe Drug Cocktail)Cohort 1b (200 mg Lasmiditan+Probe Drug Cocktail)Cohort 2a (Placebo)Cohort 2b (400 mg Lasmiditan)Total
Hispanic or Latino8105831
Not Hispanic or Latino41810739
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1a (Placebo+Probe Drug Cocktail)Cohort 1b (200 mg Lasmiditan+Probe Drug Cocktail)Cohort 2a (Placebo)Cohort 2b (400 mg Lasmiditan)Total
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American4137731
White8158738
More than one race00011
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Cohort 1a (Placebo+Probe Drug Cocktail)Cohort 1b (200 mg Lasmiditan+Probe Drug Cocktail)Cohort 2a (Placebo)Cohort 2b (400 mg Lasmiditan)Total
United States1228151570
Weight
Weight(kilograms (kg))Cohort 1a (Placebo+Probe Drug Cocktail)Cohort 1b (200 mg Lasmiditan+Probe Drug Cocktail)Cohort 2a (Placebo)Cohort 2b (400 mg Lasmiditan)Total
Mean74.78 ± 13.1481.92 ± 13.7274.13 ± 11.0478.95 ± 14.6778.39 ± 13.45
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms per meter squared)Cohort 1a (Placebo+Probe Drug Cocktail)Cohort 1b (200 mg Lasmiditan+Probe Drug Cocktail)Cohort 2a (Placebo)Cohort 2b (400 mg Lasmiditan)Total
Mean27.17 ± 2.5428.18 ± 3.5125.87 ± 3.3227.14 ± 3.8827.29 ± 3.45
08

Study locations

1 site
  • Covance Daytona Beach
    Daytona Beach, Florida 32117, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in Jan 2018, 4 months.

Results were first posted in Jan 2020, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2017
First posted
Aug 16, 2017
StartActual
Aug 15, 2017
Primary completionActual
Jan 2, 2018
CompletionActual
Jan 2, 2018
Results first posted
Jan 10, 2020
Last update
Jan 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03252015
Responsible party
Sponsor
First posted
Aug 16, 2017
Start date
Aug 15, 2017
Primary completion
Jan 2, 2018
Completion
Jan 2, 2018
Results posted
Jan 10, 2020
Last update
Jan 10, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lasmiditan

Start the discussion